Press Releases

RANCHO SANTA MARGARITA, Calif., Sept. 18, 2019 /PRNewswire/ -- Healthy Hispanic Living (HHL) today launched a campaign to celebrate Hispanic Heritage Month by showcasing

LONDON, Sept. 18, 2019 /PRNewswire/ -- GSA has launched a ground-breaking pilot project on Global Wellbeing, which aims to improve student wellbeing in the Purpose-Built Student Accommodation (PBSA) sector. As the global leader in student living, GSA believes it is paramount to advance the knowledge and understanding of student wellbeing across

HARLEYSVILLE, Pennsylvania, Sept. 18, 2019 /PRNewswire/ -- Colorcon, a world leader in the development, supply and technical support of specialty products for the pharmaceutical industry, today announced the establishment of Colorcon Ventures to invest in promising companies in the pharmaceutical industry. Colorcon's business focus is on advanced coating systems, modified release technologies

LUND, Sweden, Sept. 18, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced that positive imlifidase data were highlighted in a presentation at the 19th Congress of the European Society for Organ Transplantation (ESOT) 2019 in Copenhagen, Denmark.

STOCKHOLM, Sept. 18, 2019 /PRNewswire/ -- Biovica and the SWOG Cancer Research Network have entered into an agreement to study the clinical benefit of DiviTum® using patient blood samples from SWOG 0226, a clinical trial that showed that women with metastatic hormone receptor-positive breast cancer live longer when they receive a combination of two anti-estrogen

HONG KONG and SHANGHAI, Sept. 17, 2019 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 601318) is pleased to announce Ping An Global Voyager Fund is leading an investment of US$15 M

PHILADELPHIA, Sept. 18, 2019 /PRNewswire/ -- The American Association for Cancer Research (AACR) today released its annual Cancer Progress Report

MELBOURNE, Australia, Sept. 17, 2019 /PRNewswire/ -- Antisense Therapeutics ("ANP" or the "Company") is pleased to advise that a review of the preliminary data from the 6 patients who have completed their 24 weeks of dosing in the Phase II clinical trial of ANP's immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) therapy, is indicative of a pos

HORSHAM, Pa., Sept. 17, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved ERLEADA® (apalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).1 Today's approval follows FDA Priority Re

BREA, Calif., Sept. 17, 2019 /PRNewswire/ -- Envista Holdings Corporation, a subsidiary of Danaher Corporation (NYSE: DHR), announced today the pricing of its initial public offering (IPO) of 26,768,000 shares of its common stock at a price to the public of $22.00 per share. The shares are expected to begin trading on the New York Stoc